Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Krystal Biotech (KRYS) Accumulated Depreciation & Amortization (2021 - 2025)

Krystal Biotech's Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $29.2 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $29.2 million; the TTM value through Sep 2025 reached $29.2 million, changed N/A, while the annual FY2024 figure was $21.9 million, 70.88% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $29.2 million at Krystal Biotech, up from $26.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $29.2 million in Q3 2025 and bottomed at $2.8 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $9.1 million (2023), against an average of $13.2 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 46.44% in 2022 before it surged 216.33% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.8 million in 2021, then soared by 46.44% to $4.1 million in 2022, then soared by 216.33% to $12.8 million in 2023, then surged by 70.88% to $21.9 million in 2024, then skyrocketed by 33.09% to $29.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Accumulated Depreciation & Amortization are $29.2 million (Q3 2025), $26.7 million (Q2 2025), and $24.3 million (Q1 2025).